Daily Stock Setups

EpiCept Reports Health Canada OKs Ceplene Application for Review

Posted on: Thu, 12 Nov 2009 00:17:00 EST

Symbols: EPCT

Do you know when to trade EPCT ?

Check for a PowerRating from TradingMarkets

Nov 12, 2009 (Close-Up Media via COMTEX) --
EPCT | Quote | Chart | News | PowerRating -- EpiCept Corp. announced that Health Canada has accepted for review the Company's New Drug Submission (NDS) for Ceplene (histamine dihydrochloride) for the remission maintenance of acute myeloid leukemia (AML) patients in first complete remission.

Health Canada's performance target for the completion of review and a decision is within 300 days.

"We are pleased to have completed another key milestone in our North American regulatory strategy for Ceplene," said Jack Talley, President and Chief Executive Officer of EpiCept. "As the next step in this process, we are focused on the filing of a New Drug Application for Ceplene with the U.S. Food and Drug Administration for AML remission maintenance. As previously stated, we intend to utilize the approval of Ceplene in order to establish a fully integrated specialty pharmaceutical company focused in hematology in North America."

EpiCept also announced that Israel's Ministry of Health has accepted a marketing application for Ceplene for the remission maintenance of AML patients in first remission. The Company's distribution and marketing partner for Ceplene in Israel, Megapharm, filed the application and will market Ceplene upon approval. A decision on this application is anticipated late next year.

EpiCept said that Ceplene is approved in the European Union for the remission maintenance and prevention of relapse in patients with AML in first remission. The company is continuing negotiations with prospective partners for the European marketing rights to Ceplene. In June 2009 EpiCept launched a named patient program for Ceplene in partnership with IDIS under which physicians in all major global markets excluding the U.S. can prescribe Ceplene.

EpiCept is focused on the development and commercialization of pharmaceutical products for the treatment of cancer and pain.

((Comments on this story may be sent to health@closeupmedia.com))

For full details on EpiCept Corp (EPCT) EPCT. EpiCept Corp (EPCT) has Short Term PowerRatings at TradingMarkets. Details on EpiCept Corp (EPCT) Short Term PowerRatings is available at This Link.

More News: Market Updates | Stock Alerts | All Trading News

Disclaimer:

The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.

It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.

The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302

All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.